[1]邓悦 周晓阳.免疫检查点抑制剂相关心脏毒性的临床特点及研究进展[J].心血管病学进展,2023,(10):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
　DENG YueZHOU Xiaoyang?/html>.Clinical Characteristics and Progress of?ardiac Toxicity Associated with Immune Checkpoint Inhibitors[J].Advances in Cardiovascular Diseases,2023,(10):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
点击复制

免疫检查点抑制剂相关心脏毒性的临床特点及研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年10期
页码:
905
栏目:
综述
出版日期:
2023-10-25

文章信息/Info

Title:
Clinical Characteristics and Progress of?ardiac Toxicity Associated with Immune Checkpoint Inhibitors
作者:
邓悦 周晓阳
(武汉大学人民医院心内科,湖北 武汉 430060)
Author(s):
DENG YueZHOU Xiaoyang?/html>
?Department of Cardiology,Renmin Hospital of Wuhan UniversityWuhan 430060HubeiChina)
关键词:
免疫检查点抑制剂; 心脏毒性; 临床特点
Keywords:
Immune checkpoint inhibitor; Cardiotoxicity; Clinical characteristics
DOI:
10.16806/j.cnki.issn.1004-3934.2023.10.010
摘要:
免疫检查点表达于T细胞，参与免疫耐受、免疫监视等多种免疫过程，其包括程序性死亡受体1及其配体程序性死亡受体配体1、细胞毒性T淋巴细胞相关抗原4。免疫检查点抑制剂（ICI）是一类与免疫检查点相结合的单克隆抗体，ICI与免疫检查点或其配体结合通过激活免疫监视的功能发挥抗肿瘤效应，但同时也打破了机体对自身抗原的免疫耐受平衡，使自身反应性T细胞的活性和数量明显增加，其与心肌肌球蛋白结合诱发ICI相关心肌炎；同时，白细胞介素-2、γ干扰素等炎症因子的大量释放进一步促进ICI相关心肌炎的发展，导致高死亡率。另一方面，ICI也会诱发血管炎症、促进斑块破裂，导致急性冠脉综合征。现从流行病学、危险因素、发病机制、临床表现、诊断、治疗及预后、未来展望讨论ICI相关心脏毒性。
Abstract:
Immune checkpoints such as programmed death-1(PD-1),programmed death-ligand 1(PD-L1) and cytotoxic T lymphocyte-associated antigen-4(CTLA-4) are expressed on T cells,participating in immune tolerance,immune surveillance and other immune processes. Blocking the immune checkpoints could destroy tumors by activating immune system. However,it could increase the activity and number of self-reactive T cells because of the imbalance of immune tolerance,causing ICI myocarditis by combining with autoantigen of cardiac myosin. At the same time,the release of inflammatory factors such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ)further promote the development of ICI myocarditis,leading to high mortality. On the other hand,ICI can also induce vascular inflammation and promote plaque rupture,leading to acute coronary syndrome (ACS). Therefore,this article will discuss the clinical characteristics of ICI-related cardiotoxicity from the following aspects:epidemiology,risk factors,pathogenesis,clinical manifestations,diagnosis,treatment and prognosis

参考文献/References:

[1] Tang J, Shalabi A, Hubbard-Lucey V M. Comprehensive analysis of the clinical immuno-oncology landscape[J]. Ann Oncol, 2018, 29(1): 84-91.

[2] Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs[J]. JAMA Netw Open, 2019, 2(5): e192535.

[3] Naqash A R, Moey M Y Y, Cherie Tan X W, et al. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program[J]. J Clin Oncol, 2022, 40(29): 3439-3452.

[4] Anquetil C, Salem J E, Lebrun-Vignes B, et al. Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution[J]. Circulation, 2018, 138(7): 743-745.

[5] Drobni Z D, Alvi R M, Taron J, et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque[J]. Circulation, 2020, 142(24): 2299-2311.

[6] Yan Y D, Zhao Y, Zhang C, et al. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system[J]. EClinicalMedicine, 2022, 50: 101535.

[7] Rubio-Infante N, Ramírez-Flores Y A, Castillo E C, et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis[J]. Eur J Heart Fail, 2021, 23(10): 1739-1747.

[8] Malaty M M, Amarasekera A T, Li C, et al. Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis[J]. Eur J Clin Invest, 2022: e13831.

[9] Chen X, Jiang A, Zhang R, et al. Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis[J]. Front Cardiovasc Med, 2022, 9: 882167.

[10] Chan J S K, Lakhani I, Lee T T L, et al. Cardiovascular Outcomes and Hospitalizations in Asian Patients Receiving Immune Checkpoint Inhibitors: A Population-based Study[J]. Curr Probl Cardiol, 2023, 48(1): 101380.

[11] Hamada N, Maeda A, Takase-Minegishi K, et al. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis[J]. Front Immunol, 2021, 12: 803410.

[12] Liu S, Gao W, Ning Y, et al. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis[J]. Front Immunol, 2022, 13: 908173.

[13] Liu M, Cheng X, Ni R, et al. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis[J]. Front Immunol, 2022, 13: 1006860.

[14] Abdel-Rahman O. Association between PD-L1 inhibitor, tumor site and adverse events of potential immune etiology within the US?FDA adverse event reporting system[J]. Immunotherapy, 2021, 13(17): 1407-1417.

[15] Hao Y, Lin G, Xiang J, et al. Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients[J]. Cancer Med, 2022.

[16] Xie X, Wang L, Li Y, et al. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study[J]. Front Immunol, 2022, 13: 879900.

[17] Li C, Bhatti S A, Ying J. Immune Checkpoint Inhibitors-Associated Cardiotoxicity[J]. Cancers (Basel), 2022, 14(5).

[18] Ai L, Gao J, Zhao S, et al. Nivolumab-associated DRESS in a genetic susceptible individual[J]. J Immunother Cancer, 2021, 9(10).

[19] Von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease[J]. Nat Immunol, 2010, 11(1): 14-20.

[20] Mueller D L. Mechanisms maintaining peripheral tolerance[J]. Nat Immunol, 2010, 11(1): 21-7.

[21] Parry R V, Chemnitz J M, Frauwirth K A, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms[J]. Mol Cell Biol, 2005, 25(21): 9543-53.

[22] Won T, Kalinoski H M, Wood M K, et al. Cardiac myosin-specific autoimmune T?cells contribute to immune-checkpoint-inhibitor-associated myocarditis[J]. Cell Rep, 2022, 41(6): 111611.

[23] Kushnareva E, Stepanova M, Artemeva E, et al. Case Report: Multiple Causes of Cardiac Death After the First Infusion of Atezolizumab: Histopathological and Immunohistochemical Findings[J]. Front Immunol, 2022, 13: 871542.

[24] Walunas T L, Lenschow D J, Bakker C Y, et al. CTLA-4 can function as a negative regulator of T cell activation[J]. Immunity, 1994, 1(5): 405-13.

[25] Krummel M F, Allison J P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells[J]. J Exp Med, 1996, 183(6): 2533-40.

[26] Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4[J]. J Exp Med, 2000, 192(2): 303-10.

[27] Brunner M C, Chambers C A, Chan F K, et al. CTLA-4-Mediated inhibition of early events of T cell proliferation[J]. J Immunol, 1999, 162(10): 5813-20.

[28] Dong M, Yu T, Tse G, et al. PD-1/PD-L1 Blockade Accelerates the Progression of Atherosclerosis in Cancer Patients[J]. Curr Probl Cardiol, 2023, 48(3): 101527.

[29] Lutgens E, Mulder W J M, Consortium C A. CHECKPOINT ATHERO: developing immune checkpoint-based therapeutics for atherosclerosis[J]. Eur Heart J, 2023.

[30] Chen Y, Liu Y, Wang Y, et al. Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages[J]. J Exp Clin Cancer Res, 2022, 41(1): 1.

[31] Thompson J A, Schneider B J, Brahmer J, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241.

[32] Cadour F, Cautela J, Rapacchi S, et al. Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor-induced Myocarditis[J]. Radiology, 2022, 303(3): 512-521.

[33] Barham W, Guo R, Park S S, et al. Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy[J]. Front Immunol, 2020, 11: 561083.

[34] Mirabel M, Callon D, Bruneval P, et al. Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors[J]. JACC CardioOncol, 2020, 2(3): 511-514.

[35] Schneider B J, Naidoo J, Santomasso B D, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update[J]. J Clin Oncol, 2021, 39(36): 4073-4126.

[36] Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv264-iv266.

[37] Peleg Hasson S, Salwen B, Sivan A, et al. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis[J]. Clin Res Cardiol, 2021, 110(1): 50-60.

[38] Zhou B, Li M, Chen T, et al. Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma[J]. Front Med (Lausanne), 2022, 9: 866068.

[39] Zhao L Z, Liu G, Li Q F, et al. A case of carrelizumab-associated immune myocarditis[J]. Asian J Surg, 2022, 45(1): 496-497.

[40] Zhang C, Qin S, Zuo Z. Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis[J]. J Oncol Pharm Pract, 2022, 28(6): 1350-1356.

[41] Yang Y, Wu Q, Chen L, et al. Severe immune-related hepatitis and myocarditis caused by PD-1 inhibitors in the treatment of triple-negative breast cancer: a case report[J]. Ann Transl Med, 2022, 10(7): 424.

[42] Lin Y, Yuan X, Chen L. Immune myocarditis related to sintilimab treatment in a patient with advanced lung adenocarcinoma: A case report[J]. Front Cardiovasc Med, 2022, 9: 955527.

[43] Ji H, Wen Z, Liu B, et al. Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress[J]. Front Immunol, 2022, 13: 995121.

[44] Yang Y, Xu L, Wang D, et al. Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report[J]. Immunotherapy, 2021, 13(16): 1317-1323.

[45] Shen L, Chen H, Wei Q. Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report[J]. Front Immunol, 2021, 12: 621858.

[46] Portolés Hernández A, Blanco Clemente M, Escribano García D, et al. Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report[J]. Cardiovasc Diagn Ther, 2021, 11(4): 1013-1019.

[47] Luo Y B, Tang W, Zeng Q, et al. Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment[J]. Front Cardiovasc Med, 2021, 8: 714460.

[48] Liang S, Yang J, Lin Y, et al. Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review[J]. Front Immunol, 2021, 12: 682262.

[49] Li Y, Hu Y, Yang B, et al. Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer - A Case Report[J]. Onco Targets Ther, 2021, 14: 5309-5314.

[50] Hu X, Wei Y, Shuai X. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries[J]. Front Immunol, 2021, 12: 799077.

[51] Bai J, Li D, Yang P, et al. Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review[J]. Front Oncol, 2021, 11: 778185.

相似文献/References:

[1]祁小青 周蕾.肿瘤治疗所致Ⅰ型心脏损伤的防治[J].心血管病学进展,2020,(7):741.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.017]
　QI Xiaoqing,ZHOU Lei.Prevention and Treatment of TypeCardiac Injury Caused by Cancer Treatment[J].Advances in Cardiovascular Diseases,2020,(10):741.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.017]
[2]唐雨琦 关旭敏 方凤奇 刘基巍 夏云龙.吉西他滨引起心脏毒性的研究现状[J].心血管病学进展,2020,(9):895.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.002]
　TANG Yuqi,GUAN Xumin,FANG Fengqi,et al.Cardiotoxicity Induced by Gemcitabine[J].Advances in Cardiovascular Diseases,2020,(10):895.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.002]
[3]赵恒 谭琦 杜晓宇 谷泽慧 王亚帝.蒽环类药物致心脏毒性潜在的生物标志物研究[J].心血管病学进展,2022,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
　ZHAO HengTAN QiDU XiaoyuGU ZehuiWANG Yadi.Potential Biomarkers of Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2022,(10):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[4]古力尼尕尔·麦麦提吐尔孙 付真彦.肺癌靶向治疗药物EGFR-TKI与其心脏毒性的研究进展[J].心血管病学进展,2022,(2):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]
　GULINIGAER·Maimaitituersun,FU Zhenyan.EGFR-TKI and Its Cardiotoxicity in Lung Cancer[J].Advances in Cardiovascular Diseases,2022,(10):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]
[5]肖乾凤 王斯 刘燕扬 魏欣.免疫检查点抑制剂相关性心肌炎的诊治[J].心血管病学进展,2022,(7):610.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
　Inhibitors-Related Myocarditis.Diagnosis and Treatment of Immune Checkpoint[J].Advances in Cardiovascular Diseases,2022,(10):610.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[6]杨懿 牟云飞 任福强 黄鑫 王园.表皮生长因子受体酪氨酸激酶抑制剂用于非小细胞肺癌术后辅助治疗的心脏毒性回顾性分析[J].心血管病学进展,2022,(8):763.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.023]
　YANG Yi,MU Yunfei,REN Fuqiang,et al.A Retrospective Analysis of EGFR-TKIs-Induced Cardiotoxicity in Postoperative Adjuvant Therapy for Non-Small Cell Lung Cancer[J].Advances in Cardiovascular Diseases,2022,(10):763.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.023]
[7]王鹏 王鑫 张瑶 张经泽 贺世豪 李瑾.内质网应激在阿霉素心脏毒性中作用的研究进展[J].心血管病学进展,2023,(4):341.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.012]
　WANG Peng,WANG Xin,ZHANG Yao,et al.Role of Endoplasmic Reticulum Stress?n the Cardiotoxicity of Doxorubicin[J].Advances in Cardiovascular Diseases,2023,(10):341.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.012]
[8]孙睿 王阿曼.肿瘤免疫治疗相关动脉粥样硬化的研究进展[J].心血管病学进展,2023,(7):585.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.003]
　SUN Rui,WANG Aman.Atherosclerosis Associated with Cancer Immune Therapy[J].Advances in Cardiovascular Diseases,2023,(10):585.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.003]
[9]陆睿 廖祎 王敏 林心情 鲁明军.免疫检查点抑制剂相关动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2024,(2):141.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.010]
　LU Rui,LIAO Yi,WANG Min,et al.Research Progress on Mechanism and Clinical Significance of Immune Checkpoint Inhibitor Related Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(10):141.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.010]
[10]李登科 张伟 黄从新.SIRT1介导的信号通路在阿霉素诱导心脏毒性中的作用机制[J].心血管病学进展,2024,(3):257.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.015]
　LI Dengke,ZHANG Wei,HUANG Congxin.The Mechanisms of SIRT1-Mediated Signal Pathway in Doxorubicin-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2024,(10):257.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.015]
[11]代虎威 王馨焱 李松珊 温泽宇 曾康 杨滨.免疫检查点抑制剂相关心肌炎的诊断及管理研究进展[J].心血管病学进展,2022,(10):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
　Immune Checkpoint Inhibitor-Associated Myocarditis.Diagnosis and Management of[J].Advances in Cardiovascular Diseases,2022,(10):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]

更新日期/Last Update: 2023-11-15